Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (Nasdaq: NBIX) appointed three new Senior Vice Presidents as it advances its next phase of growth, expands its commercial portfolio and progresses its neuroscience pipeline. The moves include hiring Bret Paulson as SVP, Market Access, and promoting David Bradfute to SVP and Global Head of Intellectual Property, and Aaron Vosburgh to SVP, Finance and Accounting.
Paulson will lead global market access strategy and payer relationships. Bradfute will direct global IP strategy and serve as Managing Director of Neurocrine Switzerland GmbH in Basel. Vosburgh will oversee enterprise financial strategy, including capital allocation, long-range planning and portfolio investment alignment.
Neurocrine Biosciences (Nasdaq: NBIX) appointed Samir Siddhanti as Chief Business Officer and member of its executive Management Committee, effective July 21, 2026. He will lead enterprise growth strategy, including business development, corporate strategy, alliance management and program management to maximize value from Neurocrine's pipeline.
Siddhanti joined Neurocrine in 2017 and most recently served as Vice President, Business Development. He led multiple strategic transactions, notably Neurocrine's $2.9 billion acquisition of Soleno Therapeutics, and serves as Program Team Leader for direclidine in schizophrenia and bipolar disorder.
Neurocrine Biosciences (Nasdaq: NBIX) will release its second quarter 2026 financial results on July 30, 2026, followed by a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET). The webcast and replay will be available in the Investors section of neurocrine.com.
Neurocrine Biosciences (Nasdaq: NBIX) has initiated a Phase 2 open-label, single-arm study of crinecerfont (CRENESSITY) in 20 children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH).
The 24-week study will primarily assess safety and tolerability, with secondary endpoints evaluating pharmacokinetics and hormone biomarker effects. Results are expected to support a supplemental U.S. New Drug Application to expand crinecerfont’s indication to patients under 4 years. Neurocrine also reached target enrollment for a separate Phase 2 CAH study in the EU in children from birth to under 2 years.
Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, reported new Phase 3 VYKAT XR (diazoxide choline) data in Prader-Willi syndrome at ENDO 2026. After a 16-week randomized withdrawal, restarting VYKAT XR led to HQ-CT hyperphagia score improvements by Week 13, sustained through two years.
Continuous VYKAT XR treatment maintained benefits, with smaller but durable HQ-CT gains. Over three years, VYKAT XR showed statistically significant hyperphagia reductions versus PATH for PWS natural history controls and sustained improvements across all six PWSP behavioral domains, while BMI remained relatively stable.
Neurocrine Biosciences (Nasdaq: NBIX) reported the first retrospective case series of CRENESSITY (crinecerfont) in 15 pediatric and adult patients with classic congenital adrenal hyperplasia due to 11β‑hydroxylase deficiency, presented at ENDO 2026.
Androstenedione and adrenal precursors fell markedly, with median decreases of 92% in DOC, 95% in 11‑deoxycortisol, and 65% in androstenedione among patients with elevated baseline levels. Fourteen of 15 patients reduced glucocorticoid doses, and 2 of 5 on antihypertensives lowered or stopped these drugs. Hormone normalization was seen as early as one month, and blood pressure improved in adults. The case series is described as preliminary, early evidence supporting CRENESSITY’s efficacy and safety in this rare subtype, where the drug is already approved as an adjunct to glucocorticoids for classic CAH regardless of enzyme deficiency.
Neurocrine Biosciences (Nasdaq:NBIX) reported two-year Phase 3 CAHtalyst Pediatric data for CRENESSITY (crinecerfont) in children with classic congenital adrenal hyperplasia at ENDO 2026. Among patients with advanced bone age, mean bone age SDS fell 1.12 and a subset showed a 4.7 cm gain in predicted adult height. A U.S. caregiver survey (n=29) found 100% overall satisfaction, willingness to recommend treatment, and greater optimism about long-term outcomes. CRENESSITY was generally well tolerated through two years, with no new safety signals and sustained glucocorticoid reductions linked to improved insulin resistance, weight and BMI.
Neurocrine Biosciences (NASDAQ:NBIX) reported new two-year Phase 3 CAHtalyst Adult data on CRENESSITY (crinecerfont) in classic congenital adrenal hyperplasia at ENDO 2026.
Adults on CRENESSITY showed sustained glucocorticoid dose reductions (mean -38%), improved weight, BMI, insulin resistance, favorable bone trends, high treatment satisfaction, and no new safety signals.
Neurocrine Biosciences (Nasdaq: NBIX) reported new 48-week KINECT 4 post-hoc data on INGREZZA (valbenazine) for tardive dyskinesia. About 94% of patients achieved either symptomatic remission or a ≥30% AIMS score reduction.
A separate Medicare claims study of 176,000+ TD patients found 90% had hepatic risk factors; INGREZZA is the only VMAT2 inhibitor with approved dosing in hepatic impairment.
Neurocrine Biosciences (Nasdaq: NBIX) reported clinician-reported data on INGREZZA (valbenazine) in 30 individuals with tardive dyskinesia and intellectual and developmental disabilities.
Nearly all showed reduced TD severity; 89% improved within four weeks, with broad gains in functional, physical, and socio-emotional outcomes, including independence, emotions, socializing, dexterity, and speech.